Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Nirogacestat, Pomalidomide, and Dexamethasone in Participants with RRMM

Trial Identifier: 208887 Sub Study 7
Sponsor: GlaxoSmithKline
Start Date: August 2022
Primary Completion Date: April 2025
Study Completion Date: March 2027
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Brazil, Bahia Salvador, Bahia, Brazil, 41253-190
Brazil, Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil, 90110-270
Canada, NS Halifax, NS, Canada, B3H 1V7
France VILLEJUIF CEDEX, France, 94805
Korea, Republic of Seoul, Korea, Republic of, 03080
Korea, Republic of Ulsan, Korea, Republic of, 44033
Mexico, Mexico City Mexico City, Mexico, 01330
Norway Oslo, Norway, 0450
Poland Lublin, Poland, 20-081
Sweden FALUN, Sweden, SE-791 82